share_log

Supernus Pharmaceuticals Reiterates FY24 Revenue $580M-$620M Vs $601.461M Est.

Benzinga ·  May 8 17:25
Supernus Pharmaceuticals Reiterates FY24 Revenue $580M-$620M Vs $601.461M Est.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment